Evaluating only Keeps’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
Founded; direct-to-consumer men's hair loss model
FUNDING
Raised $25M Series B; 500K+ customers
PRODUCT LAUNCH
Category crowded: hims, Ro, Forhims all competing on same product
Keeps was a direct-to-consumer telehealth startup focused exclusively on men's hair loss treatment (finasteride and minoxidil). It raised $35 million and built a meaningful customer base around subscription-model drug delivery. The company faced competitive destruction from two directions: hims&hers, Roman, and Ro all competed on the identical product with larger marketing budgets; and GoodRx and Amazon Pharmacy drove generic finasteride prices below $10/month, eliminating the DTC price premium. Keeps was acquired by Thirty Madison in 2023 at a valuation well below its last funding round.
Lesson
“Building a brand around a commodity drug is a viable niche until three well-capitalized competitors enter and pharmacy prices collapse to near-zero. Single-condition DTC models have zero defensibility.”